AVITA Medical, Inc. (RCEL) is a Healthcare stock trading at $10.07 (as of 2026-08-20), with a market capitalization of $311.43M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
AVITA Medical, Inc. develops regenerative tissue products in the United States, Australia, and the United Kingdom, using technology based on a patient’s own skin to create treatment solutions. Its RECELL System device is used by healthcare professionals to prepare a cell suspension from a small skin sample for treating acute thermal burns in patients 18 and older, and the company has research collaborations including the University of Colorado and Houston Methodist.
Understand AVITA Medical, Inc.: how it makes money
AVITA Medical sells regenerative tissue treatment products, led by the RECELL System, which enables healthcare professionals to produce Spray-On Skin cell suspensions derived from a patient's own skin.
Its profit engine depends on how quickly commercial RECELL-related revenue scales through its reseller channel, with resell products representing 98% of commercial revenue and a large portion of the revenue base transitioning to Recell Go (75%).
Revenue by segment (latest quarter)
Commercial ex-barter
$0.0B
Barter
$0.0B
Business quality (Mixed): The most decision-useful view comes from adoption and mix KPIs (commercial revenue, resell products share, and Recell Go transition). The bear case is strengthened by very limited reported commercial revenue in the latest quarter and continued deep operating losses (operating margin -45.7%).
Bull case
Resell products drive most commercial revenue (Resell Products Share of Commercial Revenue: 98%): This suggests the go-to-market is already heavily anchored to the resell model rather than broad diversification.
Transition momentum toward Recell Go (Revenue Base Transitioned to Recell Go: 75%): A majority of the revenue base has moved to the newer revenue base under Recell Go, which can support continued scaling within the same core ecosystem.
Revenue concentration remains focused on burn and trauma hospitals (Share of Revenue From Burn Centers and Trauma Hospitals: 90%): This indicates the company is selling into its highest target-fit clinical setting.
Bear case
Commercial revenue is very small in the latest quarter (Commercial Revenue: 0.02 USD_B): With such a small revenue base, it can be difficult to sustain operating progress or absorb execution and commercialization costs.
Continued operating losses (operating margin: -45.7%): Costs have not yet been scaled down enough to convert revenue into operating profitability.
Sales depend on a concentrated customer base and reimbursement confidence (Share of Revenue From Burn Centers and Trauma Hospitals: 90%, Physician and Burn Center Resale Reimbursement Confidence: 75%): If reimbursement confidence weakens, or if adoption stalls at these centers, commercial results could be pressured.
Adoption pipeline can take time (Value Analysis Committee stages include 60 accounts in process, 52 in evaluation, and 37 in decision): Lag between pipeline stages can slow revenue conversion from new accounts.